Currently, all marketed ADC drug molecules use a single small molecule toxin as the effective payload, but challenges such as drug resistance and limited therapeutic effects still exist. Therefore, clinical chemotherapy regimens often employ combinations of multiple drugs for combination therapy. Considering the clinical efficacy of combination chemotherapy, ADC drugs with two or more effective … Read more
ADC (Antibody-drug conjugate) is a new type of drug for cancer treatment. It is a complex formed by combining anti-tumor drugs with antibodies, allowing for precise delivery of the drug into tumor cells, thereby achieving targeted treatment of tumor cells. However, with the widespread application of ADCs, research has found that the issue of ADC … Read more
Antibody-drug conjugates (ADC) are formed by the coupling of specific targeting monoclonal antibodies and highly active cytotoxic drugs through linkers. With their unique pharmaceutical properties, ADC drugs exhibit strong anti-tumor activity in the field of cancer therapy, while also offering higher safety compared to traditional chemotherapy. In recent years, the development of ADC drugs in … Read more
*For reference only by medical professionals The latest review reports that ADC drug resistance is related to antigen expression, ADC processing, and payload efficacy. Antibody-drug conjugates (ADC) are formed by the conjugation of specific targeting monoclonal antibodies and highly active cytotoxic drugs via linkers. With their unique pharmacological properties, ADC drugs exhibit powerful anti-tumor activity … Read more
